Sökning: onr:"swepub:oai:DiVA.org:uu-270951" > The Risk of Distant...
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04794naa a2200469 4500 | |
| 001 | oai:DiVA.org:uu-270951 | |
| 003 | SwePub | |
| 008 | 160105s2015 | |||||||||||000 ||eng| | |
| 009 | oai:portal.research.lu.se:publications/62d7ecdb-8a6c-4dbd-8add-f2b34e1535f2 | |
| 009 | oai:swepub.ki.se:511909 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2709512 URI |
| 024 | 7 | a https://doi.org/10.1016/j.juro.2015.07.0822 DOI |
| 024 | 7 | a oai:portal.research.lu.se:publications/62d7ecdb-8a6c-4dbd-8add-f2b34e1535f22 URI |
| 024 | 7 | a https://ki.se/en/research/search-research-information?t=2&query=id%3A5119092 URI |
| 040 | a (SwePub)uud (SwePub)lud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Stattin, Karlu Uppsala universitet,Ortopedi,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)karst605 |
| 245 | 1 0 | a The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml |
| 264 | 1 | b Ovid Technologies (Wolters Kluwer Health),c 2015 |
| 338 | a print2 rdacarrier | |
| 520 | a Purpose: Current EAU (European Association of Urology) guidelines state that prostate specific antigen 100 ng/ml or greater at diagnosis indicates metastatic disease. We examined the association of prostate specific antigen 100 ng/ml or greater at diagnosis with distant metastasis and prostate cancer specific survival. Material and Methods: A total of 15,635 men with prostate cancer diagnosed between 1998 and 2009 who were identified in PCBaSe (Prostate Cancer Data Base Sweden 2.0) were included in a population based registry study. Prostate cancer specific survival was compared among 3 groups, including 1,879 men with prostate specific antigen 100 ng/ml or greater and negative imaging (MO), 5,642 with distant metastases on imaging (M1) and prostate specific antigen 100 ng/ml or greater, and 3,828 with M1 and prostate specific antigen less than 100 ng/ml. A fourth group consisted of 4,286 men with prostate specific antigen 100 ng/ml or greater who had not undergone imaging (Mx). The latter men were not included in the assessment of survival. Results: Of 7,521 men with prostate specific antigen 100 ng/ml or greater who underwent imaging for staging 75% were classified with M1 disease. Only 59% of 3,527 men with prostate specific antigen 100 to 300 mg/ml had distant metastases on imaging. Five-year prostate cancer specific survival was 72% (95% CI 70-74) in men with prostate specific antigen 100 ng/ml or greater and MO, 24% (95% CI 23-25) in men with prostate specific antigen 100 ng/ml or greater and Ml, and 39% (95% CI 37-40) in men with prostate specific antigen less than 100 ng/ml and Ml. Conclusions: A fourth of men with prostate specific antigen 100 ng/ml or greater did not have distant metastases. They had twofold to threefold higher 5-year survival than men with distant metastases on imaging. Our findings strongly suggest that using prostate specific antigen 100 ng/ml or greater as an indicator of metastatic disease should be reconsidered. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a prostatic neoplasms | |
| 653 | a adenocarcinoma | |
| 653 | a prostate-specific antigen | |
| 653 | a neoplasm metastasis | |
| 653 | a Sweden | |
| 700 | 1 | a Sandin, Fredriku Univ Uppsala Hosp, Reg Canc Ctr, Uppsala, Sweden.4 aut |
| 700 | 1 | a Bratt, Olau Lund Univ, Dept Translat Med, Urol Canc Res Unit, Lund, Sweden.;Cambridge Hosp, Dept Urol, Cambridge, England.,Urological cancer, Malmö,Urologisk cancerforskning, Malmö4 aut |
| 700 | 1 | a Lambe, Mu Univ Uppsala Hosp, Reg Canc Ctr, Uppsala, Sweden.;Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden.,Department of Medical Epidemiology and Biostatistics (MEB)4 aut0 (Swepub:ki)6ff4c90e0827f27792e93a3b097d47a4 |
| 710 | 2 | a Uppsala universitetb Ortopedi4 org |
| 773 | 0 | t Journal of Urologyd : Ovid Technologies (Wolters Kluwer Health)g 194:6, s. 1594-1600q 194:6<1594-1600x 0022-5347x 1527-3792 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-270951 |
| 856 | 4 8 | u https://doi.org/10.1016/j.juro.2015.07.082 |
| 856 | 4 8 | u oai:portal.research.lu.se:publications/62d7ecdb-8a6c-4dbd-8add-f2b34e1535f2 |
| 856 | 4 8 | u https://ki.se/en/research/search-research-information?t=2&query=id%3A511909 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst. Hantera kakor